iShares MSCI Pacific ex Japan ETF EPP
56.51 USD +1.37 (+2.48%)
At closeNov 4, 2026, 4:08 PM EST
57.13 +0.62 +1.10%
After hours · Nov 4, 4:08 PM ET
56.21 Day range 56.54
48.93 52-week range 58.56
- YTD
- +11.97%
- 1 year
- +10.80%
- Market cap
- 2.22B
- EPS (ttm)
- 2.99
- P/E ratio
- 18.91
- YTD return
- +11.97%
- 1-year return
- +10.80%
- Volume
- 548.41K
- Avg volume
- 230.43K
- Open
- 56.32
- Previous close
- 55.14
- Day's range
- 56.21 – 56.54
- 52-week range
- 48.93 – 58.56
YTD +5.36 (+10.48%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 55.91
- 200-day average
- 55.20
Next earnings
Consensus EPS estimate 0.00.
About iShares MSCI Pacific ex Japan ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index consists of stocks from the following four countries or regions: Australia, Hong Kong, New Zealand and Singapore. The underlying index include large- and mid-capitalization companies and may change over time. The fund is non-diversified.
News
Disc Medicine (IRON) Achieves Positive Phase 3 Trial Results for EPP Treatment 
Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP) 
Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP) 
iShares MSCI Pacific ex Japan ETF (NYSEARCA:EPP) Sees Large Growth in Short Interest 
Godzilla's Rebirth: The Yen Roars And Shakes Up Markets 
Japan Inflation Picks Up as Rate-Boost Bets Firm 
SCENESSE® approved for EPP in Canada 
GondolaBio Announces Positive Phase 2a Results Demonstrating 79% Plasma Protoporphyrin IX Reduction and Disease-Modifying Potential of PORT-77 for Erythropoietic Protoporphyria 
Why Japan's $70 billion-plus intervention and a rate hike didn't prop up the yen more 
Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients
Your note
Sign in to keep a note on EPP — it syncs with the Stock Master app.